MX2019014430A - Anticuerpos humanos contra bet v 1 y metodos de uso de los mismos. - Google Patents

Anticuerpos humanos contra bet v 1 y metodos de uso de los mismos.

Info

Publication number
MX2019014430A
MX2019014430A MX2019014430A MX2019014430A MX2019014430A MX 2019014430 A MX2019014430 A MX 2019014430A MX 2019014430 A MX2019014430 A MX 2019014430A MX 2019014430 A MX2019014430 A MX 2019014430A MX 2019014430 A MX2019014430 A MX 2019014430A
Authority
MX
Mexico
Prior art keywords
antibodies
bet
fagales
allergens
methods
Prior art date
Application number
MX2019014430A
Other languages
English (en)
Inventor
Vishal Kamat
Jamie M Orengo
Andrew J Murphy
Ashok T Badithe
Yashu Liu
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2019014430A publication Critical patent/MX2019014430A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En el presente documento se proporcionan anticuerpos que se unen a alérgenos de Fagales, alérgenos relacionados con Fagales, polen de abedul o Bet v 1, composiciones que comprenden los anticuerpos, ácidos nucleicos que codifican los anticuerpos y métodos para usar los anticuerpos. Según ciertas formas de realización, los anticuerpos son anticuerpos monoclonales completamente humanos que se unen a Bet v 1. Los anticuerpos son útiles para unirse Bet v 1 in vivo, evitando así la unión del alérgeno a la IgE preformada sobre la superficie de los mastocitos o basófilos. Al hacerlo, los anticuerpos actúan para prevenir la liberación de histamina y otros mediadores inflamatorios desde los mastocitos y/o basófilos, mejorando así la respuesta desfavorable a los alérgenos de Fagales en individuos sensibilizados.
MX2019014430A 2017-06-01 2018-05-31 Anticuerpos humanos contra bet v 1 y metodos de uso de los mismos. MX2019014430A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762513872P 2017-06-01 2017-06-01
US201762571696P 2017-10-12 2017-10-12
US201862662165P 2018-04-24 2018-04-24
PCT/US2018/035366 WO2018222854A1 (en) 2017-06-01 2018-05-31 Human antibodies to bet v 1 and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2019014430A true MX2019014430A (es) 2020-07-14

Family

ID=62705709

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019014430A MX2019014430A (es) 2017-06-01 2018-05-31 Anticuerpos humanos contra bet v 1 y metodos de uso de los mismos.
MX2023000390A MX2023000390A (es) 2017-06-01 2019-11-29 Anticuerpos humanos contra bet v 1 y metodos de uso de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023000390A MX2023000390A (es) 2017-06-01 2019-11-29 Anticuerpos humanos contra bet v 1 y metodos de uso de los mismos.

Country Status (16)

Country Link
US (3) US10793624B2 (es)
EP (1) EP3630814A1 (es)
JP (3) JP6963036B2 (es)
KR (3) KR20240096746A (es)
CN (1) CN110997713B (es)
AU (2) AU2018275657B2 (es)
BR (1) BR112019025150B1 (es)
CA (1) CA3063588A1 (es)
CL (3) CL2019003508A1 (es)
CO (1) CO2019013196A2 (es)
IL (2) IL270894B2 (es)
MX (2) MX2019014430A (es)
NZ (1) NZ759513A (es)
PH (1) PH12019550238A1 (es)
WO (1) WO2018222854A1 (es)
ZA (1) ZA201907513B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240096746A (ko) * 2017-06-01 2024-06-26 리제너론 파마슈티칼스 인코포레이티드 Bet v 1에 대한 인간 항체 및 이것의 사용 방법
JP2023531968A (ja) * 2020-07-01 2023-07-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗bet v 1抗体を使用してアレルギーを治療する方法
CN113041271B (zh) * 2021-04-14 2022-12-27 浙江养生堂天然药物研究所有限公司 具有预防和抗过敏功效的组合物
WO2024200854A1 (en) 2023-03-31 2024-10-03 Alk-Abelló A/S Allergen binding antibodies suitable for treating tree pollen allergies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010194A2 (de) 1992-10-27 1994-05-11 Biomay Produktions- Und Handelsgesellschaft M.B.H. MOLEKÜLFRAGMENTE (PEPTIDE) DER HAUPTALLERGENE DER POLLEN VON BÄUMEN DER ORDNUNG $i(FAGALES)
WO1994014475A1 (en) 1992-12-21 1994-07-07 Tanox Biosystems, Inc. ALLERGEN-SPECIFIC IgA MONOCLONAL ANTIBODIES AND RELATED PRODUCTS FOR ALLERGY TREATMENT
EP0619323A1 (en) * 1993-04-09 1994-10-12 Schering-Plough Human monoclonal antibodies and processes and materials for making such antibodies
GB0002386D0 (en) 2000-02-02 2000-03-22 Novartis Nutrition Ag Therapeutic composition
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
ITMI20052517A1 (it) * 2005-12-29 2007-06-30 Lofarma Spa Varianbtio ipoallergeniche dell'allergene maggiore bet v 1 di polline di betula verrucosa
AT503297B1 (de) * 2006-05-18 2007-09-15 Biomay Ag Allergen-spezifische antikörper
PL2041177T3 (pl) 2006-06-02 2012-09-28 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
GB201002559D0 (en) 2010-02-15 2010-03-31 Circassia Ltd Birch peptides for vaccine
US10935554B2 (en) * 2013-08-23 2021-03-02 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT)
KR20240096746A (ko) 2017-06-01 2024-06-26 리제너론 파마슈티칼스 인코포레이티드 Bet v 1에 대한 인간 항체 및 이것의 사용 방법
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAx抗-CD3抗體及其用途

Also Published As

Publication number Publication date
BR112019025150B1 (pt) 2022-11-08
CO2019013196A2 (es) 2020-01-17
KR20200012892A (ko) 2020-02-05
CL2021002850A1 (es) 2022-06-24
IL270894B (en) 2022-12-01
IL270894A (en) 2020-01-30
MX2023000390A (es) 2023-02-13
ZA201907513B (en) 2022-04-28
JP2022174238A (ja) 2022-11-22
JP7458453B2 (ja) 2024-03-29
EP3630814A1 (en) 2020-04-08
IL298034B2 (en) 2024-05-01
US10793624B2 (en) 2020-10-06
KR102674000B1 (ko) 2024-06-11
IL298034A (en) 2023-01-01
AU2022200272B2 (en) 2024-10-03
JP6963036B2 (ja) 2021-11-05
AU2018275657A1 (en) 2019-12-19
CA3063588A1 (en) 2018-12-06
IL270894B2 (en) 2023-04-01
US20240083986A1 (en) 2024-03-14
CN110997713B (zh) 2024-01-02
IL298034B1 (en) 2024-01-01
JP2021112207A (ja) 2021-08-05
BR112019025150A2 (pt) 2020-06-23
PH12019550238A1 (en) 2020-10-19
CN110997713A (zh) 2020-04-10
KR20240096746A (ko) 2024-06-26
WO2018222854A1 (en) 2018-12-06
CL2019003508A1 (es) 2020-06-19
KR102329175B1 (ko) 2021-11-19
JP2020523004A (ja) 2020-08-06
JP7162097B2 (ja) 2022-10-27
US11767358B2 (en) 2023-09-26
CL2021002851A1 (es) 2022-08-19
NZ759513A (en) 2022-01-28
KR20210143327A (ko) 2021-11-26
AU2018275657B2 (en) 2022-01-06
AU2022200272A1 (en) 2022-02-10
US20210054056A1 (en) 2021-02-25
US20180346555A1 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
ZA202202846B (en) Human antibodies to fel d1 and methods of use thereof
MX2023000390A (es) Anticuerpos humanos contra bet v 1 y metodos de uso de los mismos.
WO2018170338A3 (en) High affinity mage-a1-specific tcrs and uses thereof
CA3046387A1 (en) Antibodies that specifically bind to human il-15 and uses thereof
MY146664A (en) Antibodies against human il-22 and uses therefor
WO2019133969A3 (en) Enhanced chimeric antigen receptors and uses thereof
MY171180A (en) Anti-hla-b*27 antibodies and uses thereof
WO2011094259A3 (en) Cd127 binding proteins
WO2016142783A3 (en) T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof
EP4286011A3 (en) Fcrn antibodies and methods of use thereof
EP1603949B8 (en) Antibodies against human il-21 receptor and uses therefor
EP4219552A3 (en) Il-11r binding proteins and uses thereof
EP2796469A3 (en) Novel compositions and methods for treating ige-mediated disorders
WO2015031667A3 (en) Gitr antigen binding proteins
EP2327423A3 (en) Human antibodies against human interleukin-22 (IL-22)
WO2015112749A3 (en) Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
WO2014144632A8 (en) Human pac1 antibodies
WO2019222679A3 (en) Methods of isolating allergen-specific antibodies from humans and uses thereof
EA201992651A1 (ru) АНТИТЕЛА ЧЕЛОВЕКА К Bet v 1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2014165028A8 (en) Antibodies specific to a novel epitope on cemx of human membrane-bound ige and uses thereof in treating ige-mediated diseases
WO2015077434A3 (en) Pan pollen immunogens and methods and uses thereof for immune response modulation
WO2015054217A3 (en) Methods and uses for reducing an allergic response in a subject
TH97938B (th) แอนติบอดีต่อต้าน il-22 ของมนุษย์และวิธีการใช้สำหรับการนั้น
TH1801002449A (th) แอนติบอดีต้านHtrA1และวิธีการใช้แอนติบอดีนั้น
TH136515B (th) แอนติบอดีของคนที่มีสัมพรรคภาพสูงต่อแองจิโอโพอิทิน-2-ของคน